Nicola Heffron
Vendite & Marketing presso ALEXION PHARMACEUTICALS, INC.
Patrimonio netto: 106 643 $ in data 31/05/2024
Profilo
Nicola Heffron is a professional with experience in the pharmaceutical industry.
She is currently the Senior VP, Head-Global Marketing & Market Access at Alexion Pharmaceuticals, Inc. Her former positions include Head-Global Marketing at Celgene Corp.
in 2018, Chief Commercial Officer at bluebird bio, Inc. from 2020 to 2021, and Chief Operating Officer at 2seventy Bio, Inc. from 2021 to 2023.
Ms. Heffron holds an MBA from the University of Warwick.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
2SEVENTY BIO, INC.
0.05% | 13/04/2023 | 25 211 ( 0.05% ) | 106 643 $ | 31/05/2024 |
Posizioni attive di Nicola Heffron
| Società | Posizione | Inizio |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Vendite & Marketing | 01/04/2023 |
Precedenti posizioni note di Nicola Heffron
| Società | Posizione | Fine |
|---|---|---|
| 2SEVENTY BIO, INC. | Direttore operativo | 10/03/2023 |
| CELGENE | Vendite & Marketing | 01/09/2018 |
| BLUEBIRD BIO, INC. | Corporate Officer/Principal | - |
Formazione di Nicola Heffron
| University of Warwick | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BLUEBIRD BIO, INC. | Health Technology |
| 2SEVENTY BIO, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Nicola Heffron
